Imikeraderm

Imiquimod, the active ingredient in Imikeraderm, is a immune response modifier presented as a topical formulation for skin use. It is applied to the skin to treat precancerous lesions and certain viral warts by stimulating a local immune response.

GNH USA supplies Imikeraderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imiquimod is a topical immunomodulator used to treat viral or precancerous skin lesions.

- Actinic keratosis: clears precancerous lesions on sun‑damaged skin. - Superficial basal cell carcinoma: promotes tumor regression in early‑stage basal cell carcinoma. - External genital warts (condyloma acuminata): induces immune‑mediated clearance of HPV‑related warts.

Local and systemic reactions may occur with topical use of imiquimod.

Common Side Effects: - Erythema: redness at the application site. - Itching: mild to moderate pruritus. - Burning sensation: transient heat or stinging. - Pain: discomfort during treatment. - Swelling: localized edema. - Crusting or scaling: skin flaking.

Serious or Rare Side Effects: - Severe allergic reaction: angioedema or anaphylaxis. - Stevens‑Johnson syndrome: extensive skin detachment. - Widespread ulceration: deep skin breakdown beyond treated area. - Systemic infection: secondary bacterial infection of lesions. - Persistent pigment changes: long‑lasting hyper‑ or hypopigmentation. - Lymphadenopathy: swollen regional lymph nodes.

Imiquimod should be used with caution and under medical supervision. - Hypersensitivity: discontinue if allergic reaction occurs. - Broken skin: avoid application on open wounds or abrasions. - Immunocompromised patients: monitor closely for excessive irritation. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Concomitant topical steroids: may reduce efficacy, assess need. - Store below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Imiquimod may interact with other medications that affect immune function.

Major Interactions (Avoid): - Systemic corticosteroids: may suppress intended immune response. - Biologic immunosuppressants (e.g., TNF‑α inhibitors): reduce efficacy and increase infection risk. - Chemotherapy agents: heightened local toxicity. - Live vaccines: potential for altered vaccine response. - Other topical immune modulators: risk of excessive inflammation.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish therapeutic effect. - Retinoids (topical or oral): increase skin irritation. - Phototherapy: additive photosensitivity. - Antihistamines: may mask early signs of severe reaction. - Antifungal creams: possible formulation incompatibility.